Literature DB >> 352510

Overview of cardiac pathology in relation to anthracycline cardiotoxicity.

V J Ferrans.   

Abstract

A review is presented of cardiac pathologic changes associated with acute and chronic toxicity of anthracyclines. These changes consist of cardiac dilatation, degeneration and atrophy of the muscle cells, and interstitial edema and fibrosis. The degeneration of cardiac muscle cells is a complex phenomenon that involves the myofibrils, the nucleus, the mitochondria and the membrane systems of the T-tubules, the sarcoplasmic reticulum, and the intercellular junctions. The pathogenesis of these alteration is discussed in terms of the biochemical effects of anthracyclines.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 352510

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  41 in total

1.  Myocardial toxicity of high-dose cyclophosphamide in rabbits treated with daunorubicin.

Authors:  B Isberg; C Paul; L Jönsson; U Svahn
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Increased mitochondrial emission of reactive oxygen species and calpain activation are required for doxorubicin-induced cardiac and skeletal muscle myopathy.

Authors:  Kisuk Min; Oh-Sung Kwon; Ashley J Smuder; Michael P Wiggs; Kurt J Sollanek; Demetra D Christou; Jeung-Ki Yoo; Moon-Hyon Hwang; Hazel H Szeto; Andreas N Kavazis; Scott K Powers
Journal:  J Physiol       Date:  2015-02-23       Impact factor: 5.182

3.  Characterization of the Changes in Cardiac Structure and Function in Mice Treated With Anthracyclines Using Serial Cardiac Magnetic Resonance Imaging.

Authors:  Hoshang Farhad; Pedro V Staziaki; Daniel Addison; Otavio R Coelho-Filho; Ravi V Shah; Richard N Mitchell; Balint Szilveszter; Siddique A Abbasi; Raymond Y Kwong; Marielle Scherrer-Crosbie; Udo Hoffmann; Michael Jerosch-Herold; Tomas G Neilan
Journal:  Circ Cardiovasc Imaging       Date:  2016-12       Impact factor: 7.792

4.  Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model.

Authors:  James C Lightfoot; Ralph B D'Agostino; Craig A Hamilton; Jennifer Jordan; Frank M Torti; Nancy D Kock; James Jordan; Susan Workman; W Gregory Hundley
Journal:  Circ Cardiovasc Imaging       Date:  2010-07-09       Impact factor: 7.792

Review 5.  Heart failure induced by non-cardiac drugs.

Authors:  Lars Slørdal; Olav Spigset
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

6.  Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity.

Authors:  Y J Kang; Y Chen; A Yu; M Voss-McCowan; P N Epstein
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

7.  Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits.

Authors:  E H Herman; V J Ferrans
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  Ultrastructural features of Adriamycin-induced skeletal and cardiac muscle toxicity.

Authors:  J H Doroshow; C Tallent; J E Schechter
Journal:  Am J Pathol       Date:  1985-02       Impact factor: 4.307

Review 9.  Myocardial diseases of animals.

Authors:  J F Van Vleet; V J Ferrans
Journal:  Am J Pathol       Date:  1986-07       Impact factor: 4.307

10.  Adriamycin-induced leakage of lysosomal enzymes in vitro.

Authors:  P K Singal; B MacLeod; C M Deally
Journal:  Mol Cell Biochem       Date:  1988-05       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.